From September 30 to October 2, JSC Grindeks will participate in the international exhibition „CPhI Worldwide 2008” in Frankfurt, Germany. In its exhibition stand Grindeks will offer fully integrated set of services – from the research and manufacturing of active pharmaceutical ingredients to the contract manufacturing solutions.

Chairman of the board of JSC Grindeks, Jānis Romanovskis, admits: “Highly valuable Grindeks offer of research and manufacture services allows us to compete successfully on the global pharmacy market. During the exhibition we will introduce possible cooperation partners with our products and services – research and manufacturing of active pharmaceutical ingredients, customized contract manufacturing solutions of final dosage forms, as well as advanced technologies and know-how that can fully ensure highest quality and compliance, supply reliability and competitive dynamics to all customer requirements.

The world’s leading exhibition „CPhI Worldwide 2008” presents a truly unique opportunity to exhibit in front of a global contingent of pharmaceutical professionals. This three day event will attract everyone from manufacturers and purchasers of fine chemicals and pharmaceuticals to solution providers, all in search of the latest industry developments.  This year, 1,500 companies from 140 countries will participate, planned number of visitors to exhibition is 24,500. Participation in the exhibition can generate new business alliances, renew existing partnerships, expose new innovations and strengthen the network of a company.

You are kindly invited to visits our stand nr. 42K41 (Hall 4.2) and to get to know more about JSC Grindeks and its services. We are open for co-operation!

Overview of JSC Grindeks

JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main activity is research, development, production and sales of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of Grindeks products covers a successful combination of original products and generics. It includes the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics.

The holding company of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia. It has representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of Riga Stock Exchange.
Laila Kļaviņa,
JSC Grindeks
Head of Department of communications
E-mail: laila.klavina@grindeks.lv
Phone: 67083370, 29256012